Know Cancer

forgot password

Molecular Correlates of Sensitivity and Resistance to Therapy in Prostate Cancer

18 Years
Open (Enrolling)
Prostate Cancer, Metastatic Prostate Cancer

Thank you

Trial Information

Molecular Correlates of Sensitivity and Resistance to Therapy in Prostate Cancer

Inclusion Criteria:

- 18 years of age or older and ability to adequately understand and give informed

- Local (prostate or prostate bed) recurrent CRPC or metastatic disease to soft tissue
or bone at sites accessible to biopsy with minimal risk of complications

- Platelet count >50,000; WBC >2,000, Hgb >8.0, INR<1.5; PTT<45

- No history of excessive unexplained bleeding from previous surgery

- One of the following:

- Metastatic castration sensitive prostate cancer or;

- Castration resistant prostate cancer as defined by serum testosterone < 50 ng/ml
and one of the following:

- PSA level of at least 2 ng/ml that has risen on at least 2 successive occasions
at least 1 week apart. Evaluable disease progression by modified RECIST
(Response Evaluation Criteria in Solid Tumors)

- Progression of metastatic bone disease on bone scan with > 2 new lesions

Exclusion Criteria:

- Patients unable to stop chronic anticoagulation with warfarin or lovenox for less
than 3 days

- Serious or uncontrolled infection

- Treatment with a VEGF inhibitor (such as Avastin) within the past 28 days.

Type of Study:


Study Design:

Observational Model: Case-Only, Time Perspective: Cross-Sectional

Outcome Measure:

Tissue from biopsies and blood collection will be used to study both sensitivity and resistance to prostate cancer treatment.

Outcome Time Frame:

Blood samples and biopsies are obtained on Day 1 of the study.

Safety Issue:


Principal Investigator

Bruce Montgomery, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Washington


United States: Institutional Review Board

Study ID:




Start Date:

September 2009

Completion Date:

September 2015

Related Keywords:

  • Prostate Cancer
  • Metastatic Prostate Cancer
  • Prostate cancer
  • Metastatic
  • Sensitivity
  • Resistance
  • Prostatic Neoplasms



Harborview Medical Center Seattle, Washington  98104
UWashington Seattle, Washington  98195